Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells

Journal of Cellular Physiology

Volumn 226, Issue 7, 2011, Pages 1741-1749

  Godinho, Marcia ^a   Meijer, Danielle ^a   Setyono Han, Buddy ^a   Dorssers, Lambert C J ^a   Van Agthoven, Ton ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER ANTIESTROGEN RESISTANCE 4; MESSENGER RNA; ONCOPROTEIN; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BCAR4 GENE; BREAST CANCER; CANCER CELL CULTURE; CANCER SURVIVAL; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; ONCOGENE; OOCYTE; OVERALL SURVIVAL; PLACENTA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CATTLE; CELL LINE, TUMOR; CELL PROLIFERATION; CRK-ASSOCIATED SUBSTRATE PROTEIN; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR MODULATORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HAPLORHINI; HUMANS; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; ONCOGENES; OOCYTES; PLACENTA; PREGNANCY; RABBITS; RNA INTERFERENCE; RNA, MESSENGER; TAMOXIFEN; TIME FACTORS; TRANSFECTION; TUMOR BURDEN;

BOVINAE; CALLITHRIX JACCHUS; CERCOPITHECUS AETHIOPS; MACACA MULATTA; MUS MUSCULUS; ORYCTOLAGUS CUNICULUS;

EID: 79955044468     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22503     Document Type: Article

References (61)

1. Arpino G, De Angelis C, Giuliano M, Giordano A, Falato C, De Laurentiis M, De Placido S. 2009. Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer. Oncology 77:23-37.
2. Baselga J, Swain SM. 2009. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9(7): 463-475.
3. Berns EMJJ, Foekens JA, Van Putten WLJ, Van Staveren IL, Portengen H, De Koning WCH, Klijn JGM. 1992. Prognostic factors in human primary breast cancer: Comparison of c-myc and HER2/neu amplification. J Steroid Biochem Mol Biol 43:13-19.
4. Berns EMJJ, Foekens JA, Van Staveren IL, Van Putten WLJ, De Koning HYWCM, Portengen H, Klijn JGM. 1995. Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment. Gene 159:11-18.
5. Braude P, Bolton V, Moore S. 1988. Human gene expression first occurs between the four- and eight-cell stages of preimplantation development. Nature 332:459-461.
6. Brinkman A, De Jong D, Tuinman S, Azaouagh N, Van Agthoven T, Dorssers LCJ. 2010. The substrate domain of BCAR1 is essential for anti-estrogen-resistant proliferation of human breast cancer cells. Breast cancer Res Treat 120:401-408.
7. Brummelkamp TR, Bernards R. 2003. New tools for functional mammalian cancer genetics. Nat Rev Cancer 3:781-789.
8. Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y, Skaar TC, Gomez B, O'Brien K, Wang Y, Hilakivi-Clarke LA. 2003. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22:7316-7339.
9. Dorssers LCJ, Veldscholte J. 1997. Identification of a novel breast-cancer-anti-estrogen-resistance (BCAR2) locus by cell-fusion-mediated gene transfer in human breast-cancer cells. Int J Cancer 72:700-705.
10. Dorssers LCJ, Van Agthoven T, Dekker A, Van Agthoven TLA, Kok EM. 1993. Induction of antiestrogen resistance in human breast cancer cells by random insertional mutagenesis using defective retroviruses: Identification of bcar-1, a common integration site. Mol Endocrinol 7:870-878.
11. Dorssers LCJ, Van Agthoven T, Brinkman A, Veldscholte J, Smid M, Dechering KJ. 2005. Breast cancer oestrogen independence mediated by BCAR1 or BCAR3 genes is transmitted through mechanisms distinct from the oestrogen receptor signalling pathway or the epidermal growth factor receptor pathway. Breast Cancer Res 7:R82-R92. (DOI:10.1186/bcr1954 C).
12. Dowsett M, Harper-Wynne C, Boeddinghaus I, Salter J, Hills M, Dixon M, Ebbs S, Gui G, Sacks N, Smith I. 2001. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 61:8452-8458.
13. Early Breast Cancer Trialists' Collaborative Group. 1998. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467.
14. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. 1998. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388.
15. Foekens JA, Rio M-C, Seguin P, Van Putten WLJ, Fauque J, Nap M, Klijn JGM, Chambon P. 1990. Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res 50:3832-3837.
16. Foekens JA, Van Putten WLJ, Portengen H, De Koning HYWCM, Thirion B, Alexieva-Figusch J, Klijn JGM. 1993. Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: Multivariate analysis. J Clin Oncol 11:899-908.
17. Gandolfi TA, Gandolfi F. 2001. The maternal legacy to the embryo: Cytoplasmic components and their effects on early development. Theriogenology 55:1255-1276.
18. Garrett TP, Mckern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Kofler M, Jorissen RN, Nice EC, Burgess AW, Ward CW. 2003. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 11(2): 495-505.
19. Godinho MF, Sieuwerts AM, Look MP, Meijer D, Foekens JA, Dorssers LC, van Agthoven T. 2010. Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer. Br J Cancer 103:1284-1291.
20. Gradishar WJ. 2005. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women. Oncology 69:1-9.
21. Gullick WJ, Love SB, Wright C, Barnes DM, Gusterson B, Harris AL, Altman DG. 1991. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 63:434-438.
22. Harvey JM, Clark GM, Osborne CK, Allred DC. 1999. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481.
23. Holbro T, Civenni G, Hynes NE. 2003. The ErbB receptors and their role in cancer progression. Exp Cell Res 284:99-110.
24. Hollestelle A, Nagel JH, Smid M, Lam S, Elstrodt F, Wasielewski M, Ng SS, French PJ, Peeters JK, Rozendaal MJ, Riaz M, Koopman DG, Ten Hagen TL, de Leeuw BH, Zwarthoff EC, Teunisse A, van der Spek PJ, Klijn JG, Dinjens WN, Ethier SP, Clevers H, Jochemsen AG, den Bakker MA, Foekens JA, Martens JW, Schutte M. 2009. Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res Treat.
25. Horwitz KB, Mcguire WL. 1978. Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor. J Biol Chem 253:2223-2228.
26. Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, Jiang J, Howat WJ, Ali S, Carroll JS. 2008. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456:663-666.
27. Hynes NE, Lane HA. 2005. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 5:341-354.
28. IBIS Investigators. 2002. First results from the International Breast Cancer Intervention Study (IBIS-I): A randomised prevention trial. Lancet 360:817-824.
29. Johnston SR, Lu B, Dowsett M, Liang X, Kaufmann M, Scott GK, Osborne CK, Benz CC. 1997. Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors. Cancer Res 57:3723-3727.
30. Kansra S, Yamagata S, Sneade L, Foster L, Ben-Jonathan N. 2005. Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol Cell Endocrinol 239:27-36.
31. Kocabas AM, Crosby J, Ross PJ, Otu HH, Beyhan Z, Can H, Tam WL, Rosa GJ, Halgren RG, Lim B, Fernandez E, Cibelli JB. 2006. The transcriptome of human oocytes. Proc Natl Acad Sci USA 103:14027-14032.
32. Liu B, Ordonez-Ercan D, Fan Z, Edgerton SM, Yang X, Thor AD. 2007. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. Int J Cancer 120:1874-1882.
33. Masiakowski P, Breathnach R, Bloch J, Gannon F, Krust A, Chambon P. 1982. Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res 10:7895-7903.
34. Massarweh S, Schiff R. 2006. Resistance to endocrine therapy in breast cancer: Exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer 13:S15-S24.
35. Meijer D, Van Agthoven T, Bosma PT, Nooter K, Dorssers LCJ. 2006. Functional screen for genes responsible for tamoxifen resistance in human breast cancer cells. Mol Cancer Res 4:379-386.
36. Mikheev AM, Nabekura T, Kaddoumi A, Bammler TK, Govindarajan R, Hebert MF, Unadkat JD. 2008. Profiling gene expression in human placentae of different gestational ages: An OPRU Network and UW SCOR Study. Reprod Sci 15:866-877.
37. Miller WR, Larionov A, Renshaw L, Anderson TJ, White S, Hampton G, Walker JR, Ho S, Krause A, Evans DB, Dixon JM. 2007. Aromatase inhibitors-Gene discovery. J Steroid Biochem Mol Biol 106:130-142.
38. Miner D, Rajkovic A. 2003. Identification of expressed sequence tags preferentially expressed in human placentas by in silico subtraction. Prenat Diagn 23:410-419.
39. Musgrove EA, Sutherland RL. 2009. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9:631-643.
40. Nishizawa H, Pryor-Koishi K, Kato T, Kowa H, Kurahashi H, Udagawa Y. 2007. Microarray analysis of differentially expressed fetal genes in placental tissue derived from early and late onset severe pre-eclampsia. Placenta 28:487-497.
41. Osborne CK. 1998. Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609-1618.
42. Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH. 2007. Pathways to tamoxifen resistance. Cancer Lett 256:1-24.
43. Robertson JFR. 1996. Oestrogen receptor: A stable phenotype in breast cancer. Br J Cancer 73:5-12.
44. Schier AF. 2007. The maternal-zygotic transition: Death and birth of RNAs. Science 316:406-407.
45. Seshadri R, Firgaira FA, Horsfall DJ, Mccaul K, Setlur V, Kitchen P. 1993. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 11:1936-1942.
46. Sieuwerts AM, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, Portengen H, Klijn JG, Foekens JA. 2005. How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: A retrospective study. Clin Cancer Res 11:7311-7321.
47. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, Mc Guire WL. 1989. Human breast cancer: Correlation of relapse and survival with amplification of HER2/neu oncogene. Science 235:177-182.
48. Speirs V, Walker RA. 2007. New perspectives into the biological and clinical relevance of oestrogen receptors in the human breast. J Pathol 211:499-506.
49. Thelie A, Papillier P, Pennetier S, Perreau C, Traverso JM, Uzbekova S, Mermillod P, Joly C, Humblot P, Dalbies-Tran R. 2007. Differential regulation of abundance and deadenylation of maternal transcripts during bovine oocyte maturation in vitro and in vivo. BMC Dev Biol 7:125.
50. Van Agthoven T, Van Agthoven TLA, Portengen H, Foekens JA, Dorssers LCJ. 1992. Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells. Cancer Res 52:5082-5088.
51. Van Agthoven T, Van Agthoven TLA, Dekker A, Foekens JA, Dorssers LCJ. 1994. Induction of estrogen independence of ZR-75-1 human breast cancer cells by epigenetic alterations. Mol Endocrinol 8:1474-1483.
52. Van Agthoven T, Van Agthoven TLA, Dekker A, Van der Spek PJ, Vreede L, Dorssers LCJ. 1998. Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells. EMBO J 17:2799-2808.
53. Van Agthoven T, Sieuwerts AM, Meijer-Van Gelder ME, Look MP, Smid M, Veldscholte J, Sleijfer S, Foekens JA, Dorssers LCJ. 2009a. Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J Clin Oncol 27:542-549.
54. Van Agthoven T, Veldscholte J, Smid M, Van Agthoven TLA, Vreede L, Broertjes M, De Vries I, De Jong D, Sarwari R, Dorssers LCJ. 2009b. Functional identification of genes causing estrogen independence of human breast cancer cells. Breast Cancer Res Treat 114:23-30.
55. Van Agthoven T, Sieuwerts AM, Meijer D, Meijer-van Gelder ME, Van Agthoven TLA, Sarwari R, Sleijfer S, Foekens JA, Dorssers LCJ. 2010. Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response. Endocr Relat Cancer 17:215-230.
56. Veronesi U, Maisonneuve P, Rotmensz N, Costa A, Sacchini V, Travaglini R, D'Aiuto G, Lovison F, Gucciardo G, Muraca MG, Pizzichetta MA, Conforti S, Decensi A, Robertson C, Boyle P. 2003. Italian randomized trial among women with hysterectomy: Tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 95:160-165.
57. Walker G, Macleod K, Williams AR, Cameron DA, Smyth JF, Langdon SP. 2007. Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer. Gynecol Oncol 106:461-468.
58. Weigelt B, Baehner FL, Reis-Filho JS. 2010. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: A retrospective of the last decade. J Pathol 220:263-280.
59. Wright C, Nicholson S, Angus B, Sainsbury JRC, Farndon J, Cairns J, Harris AL, Horne CHW. 1992. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65:118-121.
60. Young BC, Levine RJ, Karumanchi SA. 2010. Pathogenesis of preeclampsia. Annu Rev Pathol 5:173-192.
61. Zhang P, Kerkela E, Skottman H, Levkov L, Kivinen K, Lahesmaa R, Hovatta O, Kere J. 2007. Distinct sets of developmentally regulated genes that are expressed by human oocytes and human embryonic stem cells. Fertil Steril 87:677-690.